The absent expression of estrogen receptors (ER), progesterone receptors, and epidermal growth factor receptors (EGFR) coupled with an insufficient response to chemotherapy renders triple-negative breast cancer (TNBC) frequently resistant to standard breast cancer therapies [107]. This evidence concerns the gene EGFR and triple-negative breast carcinoma.